Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PR-HF botulinum antitoxin heptavalent
- Development stage
- Preclinical
- Lead developer
- Ology Bioservices
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
PR-HF botulinum antitoxin heptavalent is a therapeutic agent composed of recombinant monoclonal antibodies designed to treat botulism poisoning. Developed by Ology Bioservices, this heptavalent antitoxin targets and neutralizes seven different types of botulinum toxin, providing broad protection against the neurotoxins responsible for botulism. The program received funding from the U.S. Department of Defense to advance biodefense capabilities against botulinum threats.
02
Targets
BoNT/E (Botulinum neurotoxin type E)BoNT/C (Botulinum neurotoxin type C)BoNT/B (Botulinum neurotoxin type B)BoNT/A (Botulinum neurotoxin type A)BoNT/F (Botulinum neurotoxin type F)BoNT/G (Botulinum neurotoxin type G)BoNT/D (Botulinum neurotoxin type D)
Beyond the preview
Go deeper on PR-HF botulinum antitoxin heptavalent.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PR-HF botulinum antitoxin heptavalent.